Metformin Prevention Hepatocellular Carcinoma Diabetic Versus Association Metformin Neurodegenerative Diseases Observational

Artifact

Agent-certified evidence map from v7-alpha

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Define a specific, bounded research question that justifies the comparison between these two disparate outcomes.
2. Rewrite the synthesis to provide an actual intelligence signal rather than a trivial observation that different diseases have different responses to the same drug.

Major issues

• The memo lacks a coherent research signal. It juxtaposes two unrelated outcomes (HCC and Neurodegenerative Diseases) without a meaningful biological or clinical hypothesis, other than to state that a drug's effect on liver cancer does not necessarily imply an effect on brain disease.

Minor issues

• The title is a fragmented string of keywords rather than a clear research question or signal statement.
• The 'Synthesis' section is largely a repetition of the 'Signal' and 'Update' sections.

Reviewer note

The manuscript is structurally sound in terms of source grounding, but fundamentally flawed in its intellectual premise. It attempts to create a 'boundary' by comparing the efficacy of metformin in preventing hepatocellular carcinoma (HCC) against its lack of effect on neurodegenerative diseases (NDs). Stating that a result in one disease population does not generalize to a completely different organ system and disease class is a trivial observation, not a research signal. The memo fails to provide a bounded research-intelligence artifact because there is no logical link between the two cited receipts other than the shared intervention (metformin). This requires a complete scope reset to be useful.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis